FMP
Cybin Inc.
CYBN
AMEX
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
0.35 USD
-0.0006 (-0.171%)
About
ceo
Mr. Douglas L. Drysdale
sector
Healthcare
industry
Biotechnology
website
https://www.cybin.com
exchange
AMEX
Description
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
CIK
0001833141
ISIN
CA23256X1006
CUSIP
23256X100
Address
100 King Street West
Phone
908 764 8385
Country
CA
Employee
50
IPO Date
Sep 13, 2019
Key Executives
